A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Pyruvate Kinase Deficiency Clinical Trial

Official title:

An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03559699
• Other study ID #: AG348-C-007
• Secondary ID: 2017-003803-22
• Status: Completed
• Phase: Phase 3
• Start date: June 26, 2018
• Est. completion date: November 12, 2020

Study information

• Verified date: December 2021
• Source: Agios Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study AG348-C-007 was a multicenter study designed to evaluate the efficacy and safety of treatment with AG-348 in a minimum of 20, with up to 40, participants with pyruvate kinase (PK) deficiency, who were regularly receiving blood transfusions. The study was composed of two parts. During Part 1, Dose Optimization Period, participants started on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each participant's dose of AG-348 was sequentially increased to 20 mg twice a day, followed by 50 mg twice a day depending on their tolerance. During Part 2, Fixed-Dose Period, participants received AG-348 at their optimized dose from Part 1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: November 12, 2020
• Est. primary completion date: November 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed consent;

• Male or female, aged 18 or older;

• Presence of at least 2 mutant alleles in the Pyruvate Kinase Liver and RBC (PKLR) gene, of which at least 1 is a missense mutation;

• History of a minimum of 6 transfusion episodes in the 52-week period prior to date of informed consent;

• Complete records of transfusion history for the 52 weeks prior to the date of informed consent, including all transfusion dates, number of blood units transfused for all the transfusions, and Hb concentrations within 1 week prior to transfusion for at least 80% of the transfusions;

• Have received at least 0.8 mg of oral folic acid daily for at least 21 days prior to the first dose of study drug, to be continued daily during study participation;

• Have adequate organ function;

• Negative serum pregnancy test for women of reproductive potential;

• For women of reproductive potential as well as fertile men and their partners who are women of reproductive potential: be abstinent or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of AG-348;

• Willing to comply with all study procedures, in particular the individual transfusion trigger (TT) calculated based on 52 weeks of transfusion history, for the duration of the study.

Exclusion Criteria:

• Homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene;

• Significant medical condition that confers an unacceptable risk to participate in the study, and/or that could confound the interpretation of the study data;

• History of transfusions occurring on average more frequently than once every 3 weeks during the 52 weeks prior to date of informed consent;

• Splenectomy scheduled during the study treatment period or have undergone splenectomy within 12 months prior to signing informed consent;

• Currently enrolled in another therapeutic clinical trial. Prior participation in the PK Deficiency Natural History Study (NHS) (NCT02053480) or PK Deficiency Registry is permitted;

• Exposure to any investigational drug, device, or procedure within 3 months prior to the first dose of study drug;

• Prior bone marrow or stem cell transplant;

• Currently pregnant or breastfeeding;

• History of major surgery within 6 months of signing informed consent;

• Currently receiving medications that are strong inhibitors of CYP3A4, strong inducers of CYP3A4, strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive substrate medication) that have not been stopped for a duration of at least 5 days or 5 times their half-lives (whichever is longer) prior to start of study drug;

• Currently receiving hematopoietic stimulating agents (eg, erythropoietins [EPOs], granulocyte colony stimulating factors, thrombopoietins) that have not been stopped for a duration of at least 28 days prior to the first dose of study drug;

• History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis or other serious clinical manifestations;

• Allergy to AG-348 or its excipients;

• Currently receiving anabolic steroids, including testosterone preparations, within 28 days prior to the first dose of study drug.

Related Conditions & MeSH terms

• Anemia, Hemolytic
• Pyruvate Kinase Deficiency

Intervention

Drug:
• AG-348
Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance. Part 2 (Fixed Dose Period): Optimized dose determined in Part 1.

Locations

Country	Name	City	State
Canada	Toronto General Hospital, University Health Network	Toronto
Denmark	University of Copenhagen, Herlev Hospital	Herlev
France	Hopital Universitaire Henri Mondor	Créteil
France	Hôpital de la Timone	Marseille, Cedex 5
Ireland	St James's Hospital Department of Haematology	Dublin
Italy	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Milano
Italy	AORN Cardarelli	Napoli
Italy	AOU Policlinico, Università della Campania "Luigi Vanvitelli"	Napoli
Italy	Ospedale Galliera	Napoli
Netherlands	Universitair Medisch Centrum Utrecht	Utrecht
Thailand	Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University	Bangkok
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	Imperial College Healthcare NHS Trust, Hammersmith Hospital	London
United Kingdom	University College London	London
United Kingdom	Manchester Royal Infirmary	Manchester
United States	Emory University	Atlanta	Georgia
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	UCSF Benioff Children's Hospital	Oakland	California
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Agios Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  France,  Ireland,  Italy,  Netherlands,  Thailand,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage of Participants Experiencing an Adverse Event of Special Interest (AESI)	An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.	From Part 1 Day 1 to end of Part 2, including follow-up (Day 197)
Other	Bone Mineral Density Z-Score		Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
Other	Bone Mineral Density T-Score		Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
Primary	Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2	Reduction in transfusion burden is defined as a =33% reduction in the number of RBC units transfused during the Fixed Dose Period standardized to 24 weeks compared with the historical transfusion burden standardized to 24 weeks (Standardized Control Period). The on-study (Fixed Dose Period) transfusion burden was calculated as the total number of transfused RBC units received in the Fixed Dose Period standardized to 24 weeks.	From Part 2, Day 1 to Part 2 Week 24
Secondary	Annualized Number of RBC Units Transfused During the Study	The annualized total number of RBC units transfused during the entire study (both Part 1 and Part 2) is reported. It was calculated as the total number of RBC units transfused up to the end of Fixed Dose Period divided by the total number of days from the first dose date until the end date of Fixed Dose Period × 52.	Part 1 Day 1 to Part 2 Week 24
Secondary	Number of Transfusion Episodes in Part 2	This is the number of transfusion episodes in Part 2. The number of transfusion episodes were standardized to 24 weeks. Transfusions received over up to 3 consecutive days were counted as 1 episode.	From Part 2 Day 1 to Part 2 Week 24
Secondary	Percentage of Transfusion-Free Participants in Part 2	Transfusion-free responders were the participants who were transfusion-free in Part 2.	From Part 2 Day 1 to Part 2 Week 24
Secondary	Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2	This is the percentage of participants who achieved hemoglobin (Hb) concentrations in the normal range at least once, 8 weeks or more after a transfusion in Part 2.	From Part 2 Day 1 to Part 2 Week 24
Secondary	Percentage of Participants With Adverse Events	An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	Through 4 weeks after last dose (approximately Part 2, Week 31)